

# COVID-19 Outpatient Therapeutics Guidelines

For adult or pediatric patients with mild to moderate COVID-19 and at high-risk for progression to severe disease.



Patient tested positive?\*

Yes

Patient considered high-risk?

Yes

No\*\*

COVID-19 high-risk factors:

Patients who have risk factors and are not up to date with CDC COVID-19 vaccine recommendations are at higher risk of disease progression.

- ≥ 65 YO
- Overweight or obese
- Pregnant
- Diabetic
- Immunocompromised
- Chronic kidney disease
- Cardiovascular disease
- Chronic lung disease
- Sickle cell disease
- Neurodevelopment disorders

Other high-risk conditions identified by CDC for People with Certain Medical Conditions.



Symptoms onset ≤ 7 days?  
Symptom onset is day zero.

Yes

No\*\*

≤ 5 Days

≤ 7 Days

Consider Oral Antivirals (OAVs)

Consider IV Treatments

- Paxlovid
- Lagevrio (molnupiravir)



- Veklury (remdesivir)
- Bebtelovimab

Paxlovid is a first-line treatment; consider other treatments when Paxlovid is unavailable or not clinically indicated.

\*Proof of a positive COVID-19 PCR test is not a requirement from MDHHS or under the EUAs for COVID-19 therapeutics; consider accepting at-home test results.

\*\*For patients who don't qualify for COVID-19 outpatient treatments, provide supportive care and anticipatory guidance per National Institutes of Health and CDC Guidelines.


# Hepatic and Renal Function Considerations



Prescribers should use clinical judgment in determining need for hepatic and renal function studies. Routine pre-administration laboratory testing is not required unless clinically indicated.

# COVID-19 Treatments Main Considerations

Health care providers should review the medication-specific FDA fact sheet before prescribing.



## Paxlovid

At least  
12 YO  
&  
40 Kg

☀ Administer ASAP within **5 days** of symptom onset.

☀ Evaluate, as needed, for hepatic and renal function:

- **Normal Renal Function (eGFR  $\geq$  60 mL/min);**  
Standard Dose Pack: **300 mg** nirmatrelvir taken together with 100 mg ritonavir twice daily for 5 days.
- **Moderate Renal Impairment (eGFR  $\geq$  30 to  $<$  60);**  
Renal Dose Pack: **150 mg** nirmatrelvir taken together with 100 mg ritonavir twice daily for 5 days.
- **Not recommended in severe hepatic or renal impairment.**



☀ Obtain patient's medication list and review prior to prescribing Paxlovid for the potential of drug-drug interaction. Management of Paxlovid drug-drug-interactions tools:

- [Paxlovid Drug-Drug-Interactions list by University of Michigan](#)



- [COVID-19 Drug interactions by University of Liverpool](#)



- [FDA PAXLOVID Patient Eligibility Screening Checklist Tool](#)



## Veklury (remdesivir)

At least  
28 Days  
&  
3 Kg

☀ Administer ASAP within **7 days** of symptom onset.

☀ Perform eGFR, hepatic laboratory, and prothrombin time testing prior to initiating Veklury and during use as clinically appropriate (per FDA approval):

- **Not recommended in severe renal impairment (eGFR  $<$ 30 mL/min).**
- **Further consideration needed if elevation in transaminases.**

☀ Dose for adult or pediatric patient (ages 12 and older weighing at least 40 kg) is:

- 200 mg IV x 1 dose on Day 1, and
- 100 mg IV x 1 on Days 2-3.

☀ Dose for pediatric patient (older than 28 days weighing at least 3 kg to less than 40 kg) is:

- 5 mg/kg IV x 1 dose on Day 1, and
- 2.5 mg/kg IV x 1 on Days 2-3.
- For this group of patients use 100 mg lyophilized powder for Injection only.



☀ Observe patient for signs and symptoms of a clinically significant hypersensitivity reaction.

☀ Veklury is in limited availability. If not readily available, consider bebtelovimab.



# COVID-19 Treatments Main Considerations Cont.

Health care providers should review the medication-specific FDA fact sheet before prescribing.



## Bebtelovimab

At least  
12 YO  
&  
40 Kg

- ☀ Administer ASAP within **7 days** of symptom onset.
- ☀ Dose is 175 mg single IV injection.
- ☀ Observe patient for one hour after bebtelovimab injection.
- ☀ Give only when Paxlovid and Veklury are unavailable or not indicated.



## Lagevrio (molnupiravir)

At least  
18 YO

- ☀ Administer ASAP within **5 days** of symptom onset.
- ☀ Dose is 800 mg by mouth every 12 hours for 5 days.
- ☀ Molnupiravir is not recommended in pregnancy.
- ☀ Males and females should use effective contraception during and following treatment with molnupiravir.
- ☀ Give only when Paxlovid, Veklury and bebtelovimab are unavailable or not indicated.

### Paxlovid EUA Fact Sheet for HCPs



### Veklury Fact Sheet for HCPs



### Bebtelovimab EUA Fact Sheet for HCPs



### Lagevrio EUA Fact Sheet for HCPs



For more information please visit  
[Michigan.gov/COVIDTherapy](https://Michigan.gov/COVIDTherapy).

